Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Assiut University

Status: Completed

Conditions: Inflammatory Bowel Diseases

Treatments: Drug: Infliximab

Study type: Observational

Funder types: Other

Identifiers

NCT03445624

assiut hospitals university

Details and patient eligibility

About

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Full description

the participants will follow up the patient for 1 year in the first visit

All patients in this study will be subjected to:

1. Detailed history.

2. Careful physical examination

3. laboratory investigation

   1. complete blood picture.
   2. liver function
   3. kidney function
   4. Iron profile(serum iron ,serum ferritin
   5. ESR (erythrocyte sedimentation rate )

   g-CRP (C reactive protein) f-LDH (lactate dehydrogenase)

4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs)

5. Doppler us (mesenteric vessels)

6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

Enrollment: 60 patients

Sex: All

Ages: 15 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

• patients diagnosed ulcerative colitis at age(15-60)
• patients diagnosed crohns disease at age(15-60)k

Exclusion criteria

• liver cirrhosis and portal hypertension
• spontaneous bacterial peritonitis
• Ischemic colitis

Trial design

60 participants in 2 patient groups

patient on traditional therapy

Description:

Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)

Treatment:

Drug: Infliximab

patient on infliximab

Description:

drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months

Treatment:

Drug: Infliximab